Personal information

Verified email addresses

Activities

Employment (1)

Dr. Brünke MTC: Nuremberg, DE

2017-12-01 to present | Managing Director
Employment
Source: Self-asserted source
Joerg Bruenke

Education and qualifications (2)

University of Erlangen-Nuremberg: Erlangen, Bayern, DE

2000-01-01 to 2005-09-30 | PhD (Chair of Genetics)
Education
Source: Self-asserted source
Joerg Bruenke

University of Erlangen-Nuremberg: Erlangen, Bayern, DE

1993-11-01 to 1999-11-30 | Diploma
Education
Source: Self-asserted source
Joerg Bruenke

Professional activities (1)

International Biodeterioration Research Group : Hants, GB

2006 to 2010
Service
Source: Self-asserted source
Joerg Bruenke

Funding (1)

Kontrolle der RNA-Synthese: Vielfalt der Strategien bei Pro- und Eukaryonten

Salary award
Deutsche Forschungsgemeinschaft (Bonn, DE)
Source: Self-asserted source
Joerg Bruenke

Works (19)

Epidural infections, bacteriostatic drug effects and technical strategies for prevention

Regional Anesthesia & Pain Medicine
2022-02 | Journal article
Contributors: Joerg Bruenke; Thomas Riemann; Paul Kessler; Norman Kachel
Source: check_circle
Crossref

Quantitative Comparison of the Antimicrobial Efficiency of Leaching versus Nonleaching Polymer Materials.

World Biomedical Frontiers - Editor's Pick
2017 | Journal issue or edition
Source: Self-asserted source
Joerg Bruenke

Closed infusion systems prevent microbial contamination

Hospital Pharmacy Europe
2016 | Journal article
Source: Self-asserted source
Joerg Bruenke

Quantitative Comparison of the Antimicrobial Efficiency of Leaching versus Nonleaching Polymer Materials

Macromolecular bioscience
2016 | Journal article
Source: Self-asserted source
Joerg Bruenke

Evaluation of the chemical tightness of CSTDs

Hospital Pharmacy Europe
2015 | Journal article
Source: Self-asserted source
Joerg Bruenke

Antimikrobielle Wirksamkeit zuverlässig prüfen

Journal für Oberflächentechnik
2013 | Magazine article
Source: Self-asserted source
Joerg Bruenke

Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells

Cancer letters
2011 | Journal article
Source: Self-asserted source
Joerg Bruenke

A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells

Journal of immunology (Baltimore, Md. : 1950)
2010 | Journal article
Source: Self-asserted source
Joerg Bruenke

Antibiotic release and anti-infective effectiveness of Gentamicinpalmitate coating in uncemented titanium implants

International Journal of Nano and Biomaterials
2010-10-19 | Journal article
Source: Self-asserted source
Joerg Bruenke

A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells

Journal of immunotherapy (Hagerstown, Md. : 1997)
2008 | Journal article
Source: Self-asserted source
Joerg Bruenke

Recombinant, Single-Chain, Trivalent Tri-Specific or Bi-Specific Antibody Derivatives

2008 | Patent
Source: Self-asserted source
Joerg Bruenke

RECOMBINANT, SINGLE-CHAIN, TRIVALENT TRI-SPECIFIC OR BI-SPECIFIC ANTIBODY DERIVATIVES

2008 | Patent
Source: Self-asserted source
Joerg Bruenke

Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives

2007 | Patent
Source: Self-asserted source
Joerg Bruenke

Quality assurance for antimicrobial devices

Medical device technology
2006 | Magazine article
Source: Self-asserted source
Joerg Bruenke

Bispecific antibody devoid of Fc region and method of treatment using same

2005 | Patent
Source: Self-asserted source
Joerg Bruenke

Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16)

British journal of haematology
2005 | Journal article
Source: Self-asserted source
Joerg Bruenke

A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells

British journal of haematology
2004 | Journal article
Source: Self-asserted source
Joerg Bruenke

Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications

Journal of immunological methods
2004 | Journal article
Source: Self-asserted source
Joerg Bruenke

HLA class II antibodies in the treatment of hematologic malignancies

Seminars in oncology
2003 | Journal article
Source: Self-asserted source
Joerg Bruenke